The trade protectionism theme of the US shot back into focus as a potential major left tail risk for markets which got further aggravated by the subsequent retaliatory rhetoric from Europe and Asia.
Will China render blow for blow? It appears to be. At least China has made the stronger response. After the US government unveiled the detailed list of Chinese goods that could be soon subject to 25% tariff, China’s statement sounds tougher. A spokesman of Commerce Ministry said that China plans to immediately bring relevant U.S. practice to the dispute settlement body of the WTO, and is ready to take countermeasures on U.S. products with equal force and scale that will be published in the coming days.
Obviously, America’s list suggests that the US government targets “Made in China 2025” initiative, while China’s retaliation intends to bring Americans back to the negotiation table. John Sullivan, acting Secretary of State, will meet Chinese Ambassador the US Cui Tiankai today.
As usual, both sides are likely to issue a statement full of diplomatic rhetoric, while leaving the door open.
On a separate note, China’s private Caixin composite PMI declined to 51.8 in March, from 53.3 previously, indicating that there is a considerable moderation in economic activities. It appears that the trade war concerns have been escalated to the real sectors.
The arguments in favor of a stronger CNY, both against the USD and in TWI terms, still remain in place: positive growth differentials; on-going trade tensions which are raising tolerance levels for a stronger CNY; CNY outperformance during periods of elevated risk-aversion and an attractive carry to realized volatility ratio. The outperformance of CNY was quite noticeable during the recent turmoil in global equity markets.
Trade tips: Buy 6M EURCNH ATMF vs. ATMS put spreads, Option-based carry to exploit constructive FX view and elevated carry/vol.
FxWirePro launches Absolute Return Managed Program. For more details, visit:


JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks
Moody's Upgrades Argentina's Credit Rating Amid Economic Reforms
Energy Sector Outlook 2025: AI's Role and Market Dynamics
Bank of America Posts Strong Q4 2024 Results, Shares Rise
S&P 500 Relies on Tech for Growth in Q4 2024, Says Barclays
Rice feeds billions of people – but its role in fueling climate change is growing
US Gas Market Poised for Supercycle: Bernstein Analysts
Wall Street Analysts Weigh in on Latest NFP Data
UBS Projects Mixed Market Outlook for 2025 Amid Trump Policy Uncertainty
Stock Futures Dip as Investors Await Key Payrolls Data
Gold Cracks Below $4,500 as Safe-Haven Shine Fades; Technical Breakdown Signals Sell-on-Rallies Toward $4,000
Indonesia Surprises Markets with Interest Rate Cut Amid Currency Pressure
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026
Global Markets React to Strong U.S. Jobs Data and Rising Yields
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 



